Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404). He is also involved in the development of new radioligand therapeutics.
His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells. 4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
Latest news
- Le CQDM octroie 1,5 M$ pour un projet de recherche sur le cancer de la prostate 2020-07-20
- [Le Soleil] Cancers de la prostate : la bonne thérapie pour le bon patient… mais comment ? 2020-06-30
- Le Centre de recherche du CHU de Québec sur le point de doubler son volume d’études cliniques précoces 2019-11-05
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System
Journal ArticleAdv Radiat Oncol, 7 (4), 2022.
Bladder cancer cell lines adapt their aggressiveness profile to oxygen tension
Journal ArticleOncol Lett, 24 (1), 2022.
A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System (CKCis)
Journal ArticleJ Urol, 2022.
Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective
Journal ArticleCan Urol Assoc J, 2022.
Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion
Journal ArticleMol Metab, 62 , 2022.
Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort
Journal ArticleUrology, 2022.
Establishing metastatic prostate cancer quality indicators using a modified Delphi approach
Journal ArticleClin Genitourin Cancer, 20 (2), 2022.
Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations
Journal ArticleCan Urol Assoc J, 16 (2), 2022.
Canadian Urological Association guideline: Management of small renal masses - Full-text
Journal ArticleCan Urol Assoc J, 16 (2), 2022.
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients
Journal ArticleClin Genitourin Cancer, 20 (3), 2022.
Active projects
- National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
- Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2022-06-30
- Surveillance of Complex Renal Cysts: The SOCRATIC study, from 2019-10-01 to 2028-09-30
- Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
- Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, from 2019-07-01 to 2023-06-30
Recently finished projects
- A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease , from 2021-04-01 to 2022-03-31
- Bourse Concert pour la vie , from 2020-11-13 to 2021-11-12
- CUASF-BCC Research Grant Program , from 2020-06-06 to 2021-06-05
- Modeling Prostate Cancer in 30 using tissue engineering , from 2019-09-11 to 2020-09-10
- Projet de recherche sur le cancer de la prostate intitulé Ironman , from 2020-03-24 to 2021-03-23